Biccler JL, et al. - Researchers sought to determine prognosis of classic Hodgkin lymphoma (cHL) in the age of contemporary treatment at various milestones during follow-up. With a Nordic cohort of 2,582 patients diagnosed at ages 18 to 49 years between 2000 and 2013, they estimated 5-year relapse risks and 5-year restricted losses in expectation of lifetime for all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60) months. Observation revealed excellent outcomes for these patients; the 5-year overall survival was 95%. Patients who reach EFS24 had especially favorable outcomes, which supports limited relapse-oriented clinical follow-up.